Executive Series 26 Jun 18: Wattle Health Australia (WHA) CEO, Lazarus Karasavvidis, page-86

WHA has been approved for adult milk powder, should be "CIQ" accreditation issued by State Administration for Market Regulation (SAMR), previously AQSIQ (merged together with CFDA into SAMR).

WHA infant formula has passed SAMR/CFDA technical review, is waiting for formal approval.

Further to our announcement of 6 April 2018, WHA has passed technical evaluation for State Administration for Market Regulation (SAMR, formerly known as CFDA) accreditation for China. WHA is now waiting for formal approval and attainment of SAMR, on receipt of which revenue is projected to reach in excess of $140 million over a 42-month period in the China market.

Cash at bank at the end of the quarter was around $50 million with nil debt.

https://www.aqsiq.net/ciq.htm

State Administration for Market Regulation (SAMR), merged and are undertaking the responsibilities previously held by the State Administration for Industry and Commerce (SAIC),General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ), the Certification and Accreditation Administration (CAC), the Standardization Administration of China (SAC) and the China Food and Drug Administration (CFDA).

“WHA signs a minimum supply term agreement with International Supplies and Distribution Company Pty Ltd amounting to revenue of more than $100 million over 42 months
• WHA enters into a fully funded transformational joint venture with Organic Dairy Farmers of Australia
• WHA secures a distribution agreement with Metcash Trading for WHA’s Australian Natural Baby Food range
• WHA appoints leading e-commerce provider, Quality Brands International Direct, to provide access to major export markets
• WHA signs a minimum supply agreement with Chinese State-Owned Enterprise, Shandong Weihai Port International Trade Co. Ltd., amounting to revenue of $34 million over 36 months”